Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
Express Scripts
Moodys
Merck

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,097,648

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,097,648 protect, and when does it expire?

Patent 8,097,648 protects HALAVEN and is included in one NDA.

This patent has forty-one patent family members in twenty-two countries.

Summary for Patent: 8,097,648
Title:Methods and compositions for use in treating cancer
Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Towle; Murray J. (Auburn, NH), Seletsky; Boris M. (Andover, MA), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonderry, NH)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:11/282,505
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,097,648

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,097,648

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502932   Start Trial
Australia 2003284242   Start Trial
Australia 4573999   Start Trial
Australia 762998   Start Trial
Belgium 2011C028   Start Trial
Brazil 9911326   Start Trial
Canada 2335300   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKinsey
Medtronic
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.